- Generic Name: fludarabine
- Dosage Forms: n.a.
- Other Brand Names: Fludara, Oforta
What is Fludarabine Phosphate?
Treatment of B-cell CLL (B-CLL) in patients refractory to at least one standard alkylating agent-containing regimen (e.g., chlorambucil with or without prednisone) or whose disease has progressed during treatment; considered a drug of choice. Has been designated an orphan drug by FDA for this use.
Used in the management of previously untreated CLL (has been designated an orphan drug by FDA for this use) or in leukemia that was contemporaneously responsive to standard therapy.
Non-Hodgkin’s Lymphoma
Treatment of low-grade, advanced (stage III or IV) adult non-Hodgkin’s lymphoma that failed or relapsed after previous therapy; has been designated an orphan drug by FDA for use in this condition.
Acute Leukemias
Treatment of either acute myeloid (myelogenous, nonlymphocytic) leukemia (AML, ANLL) or acute lymphocytic leukemia (ALL) refractory to conventional therapy or which has relapsed following remission.
Severe toxicity, associated with the relatively high dosages that appear to be necessary for adequate response in these leukemias, may preclude use of the drug as monotherapy for remission induction of these cancers.
Prolymphocytic Leukemia and Prolymphocytoid Variant
Palliative treatment of prolymphocytic leukemia (PLL) or prolymphocytoid chronic lymphocytic leukemia (CLL-Pro) refractory to standard chemotherapy (e.g., chlorambucil and prednisone).
Hairy Cell Leukemia
Treatment of hairy cell leukemia (leukemic reticuloendotheliosis); other drugs (e.g., cladribine, pentostatin) considered the initial therapies of choice.
Waldenstrom’s Macroglobulinemia
Treatment of refractory macroglobulinemia.
Mycosis Fungoides
Treatment of mycosis fungoides, a form of cutaneous T-cell lymphoma.